Open-label dose-escalation study of oral 1-octanol in patients with essential tremor

被引：38
|
作者：
Shill, HA
Bushara, KO
Mari, Z
Reich, M
Hallett, M
机构：
[1] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA
来源：
NEUROLOGY | 2004年 / 62卷 / 12期
关键词：
D O I：
10.1212/WNL.62.12.2320
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Twenty-one single oral doses of 1-octanol were given to patients with essential tremor ( ET) in an open-label dose-escalation study. The drug was well tolerated up to 64 mg/kg. The main side effect was an unusual taste. No overt intoxication was seen. There was evidence for efficacy, with a significant reduction in tremor amplitude as measured by accelerometry and handwriting that was maximal at 2 hours. Higher doses may produce more sustained benefit.
引用
收藏
页码：2320 / 2322
页数：3
相关论文
共 50 条
  • [21] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [23] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [24] Safety of intranasal insulin administration in patients undergoing cardiovascular surgery: An open-label, nonrandomized, dose-escalation study
    Nakadate, Yosuke
    Kawakami, Akiko
    Oguchi, Takeshi
    Omiya, Keisuke
    Nakajima, Hiroyuki
    Yokomichi, Hiroshi
    Sato, Hiroaki
    Schricker, Thomas
    Matsukawa, Takashi
    JTCVS OPEN, 2024, 17 : 172 - 182
  • [25] Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
    Chen, Qiuyan
    Tang, Linquan
    Liu, Na
    Han, Feng
    Guo, Ling
    Guo, Shanshan
    Wang, Jianwei
    Liu, Huai
    Ye, Yanfang
    Zhang, Lu
    Liu, Liting
    Wang, Pan
    Li, Yingqin
    He, Qingmei
    Yang, Xiaoqun
    Tang, Qingnan
    Li, Yang
    Liang, YuJing
    Sun, XueSong
    Xie, Chuanmiao
    Mo, Yunxian
    Guo, Ying
    Sun, Rui
    Mo, Haoyuan
    Cao, Kajia
    Guo, Xiang
    Zeng, Musheng
    Mai, Haiqiang
    Ma, Jun
    CANCER COMMUNICATIONS, 2018, 38
  • [26] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [27] Open-label, phase I/II dose-escalation study of ARANESP™ in patients with chronic anemia of cancer.
    Glaspy, J
    Meza, L
    Smith, R
    Fleishman, A
    Mendes, E
    Colowick, A
    BLOOD, 2000, 96 (11) : 154B - 155B
  • [28] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [29] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
  • [30] An Open-Label, Sequential Dose-Escalation, Safety, and Tolerability Study of Rimabotulinumtoxinb in Subjects With Cervical Dystonia
    Chinnapongse, Robert
    Pappert, Eric J.
    Evatt, Marian
    Freeman, Alan
    Birmingham, William
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (11) : 703 - 710
12345